ZNF644

Across TCGA pan-cancer cohorts, ZNF644 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF644 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZNF644 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF644 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where ZNF644 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.778	0.264	.004	19	view →
PDAC	OS	Median	All	0.574	0.240	.010	10	view →
CCRCC	DFS	Median	All	0.932	0.646	.016	8	view →
LSCC	OS	Median	All	1.000	0.800	.044	3	view →
HNSC	DFS	Median	III,IV	0.939	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF644–LUAD (DFS)

Open the LUAD breakdown →